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Abstract: Background. We previously identiﬁed by ﬂow
cytometry a Lineage-CD44þ (Lin-CD44þ) subpopulation of
cells with cancer stem cell properties in head and neck squa-
mous cell carcinoma (HNSCC). We now correlate clinical and
histologic factors with Lin-CD44þ cell frequency.
Methods. The study included 31 patients with HNSCC, of
whom 87% had stage IV disease. The frequency of Lin-CD44þ
cells and the success of xenografting patient tumors in mice
were correlated with clinical and pathologic data.
Results. The mean frequency of Lin-CD44þ cells was 25%
(0.4%–81%). It was 36% in patients who had recurrence ver-
sus 15% for those without recurrence (p ¼ .04). Successful
xenograft implantation occurred in 53%. Seventy-ﬁve percent
of patients with successful xenografts had recurrence versus
21% of patients with unsuccessful xenografts (p ¼ .003).
Conclusions. Successful xenograft implantation and a high
frequency of Lin-CD44þ cells correlate with known poor prognostic
factors such as advanced T classiﬁcation and recurrence. These
ﬁndings may support the stem cell concept in HNSCC. VC 2011
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Head and neck squamous cell carcinoma (HNSCC)
affects more than 40,000 new patients in the United
States each year.1 Advances in treatment have
improved quality of life, and there have been improve-
ments in survival associated with nasopharyngeal car-
cinoma2 and human papillomavirus (HPV)–associated
oropharyngeal carcinomas.3,4 However, for the typical
HNSCCs associated with tobacco and alcohol use, sur-
vival rates have changed little in the last 40 years.4
The mortality rate remains high because of advanced
and recurrent locoregional disease, as well as distant
metastases. Better understanding of the biology of
HNSCC is required to deﬁne relevant targets and to
develop novel therapeutic approaches.
Stem Cells in Cancer. Stratiﬁed squamous epithe-
lium contains a basal layer of cells, some or all of which
are the source of epithelial replenishment during the
normal life cycle of the tissue and in response to injury.
In other words, normal stem cells in the basal layer are
the functional reservoir for the normal homeostasis
within a correctly regulated squamous cell microenvir-
onmental niche. Such cells generate daughter cells on
division, with some remaining as a stem cell (self-
renewing) and some morphologically and functionally
maturing as they begin their migration toward the sur-
face and die. This migration and regulated response to
environmental signals from their niche is normal, with
morphologic and functional heterogeneity.
Epithelial tumors such as HNSCC contain both mor-
phologic and functional cellular heterogeneity,5,6 as
would be expected if they arise from dysregulated stem
or progenitor cells as opposed to the simple clonal expan-
sion of a mutated cell. This observation supports the can-
cer stem cell hypothesis for HNSCC: normal stem or
progenitor cells become dysregulated, leading to a cancer
stem cell, with the tumor hierarchically organized. Some
cells retain the self-renewal capacity inherent in the nor-
mal stem cell, and these cancer stem cells drive tumori-
genesis through self-renewal and differentiation. The
cancer stem cells also give rise to a large population of
differentiated progeny that make up the bulk of tumor
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but lack the tumorigenic potential of the stem cell, just
as the cells above the basal layer of the stratiﬁed epithe-
lium are destined to die as they migrate to the surface.
In support of this hypothesis, recent studies have shown
that, similar to leukemia and other hematologic malig-
nancies,7–11 tumorigenic and nontumorigenic popula-
tions of cancer cells can be isolated from a variety of
tumor types on the basis of their expression of cell-sur-
face markers.12,13 Although not all accept this
hypothesis,14 support of the cancer stem cell hypothesis
in a variety of solid tumor types remains strong.15,16
Numerous prognostic markers exist for HNSCC,
with clinical and histologic factors remaining the most
commonly used. Reliable correlates of the likelihood of
recurrence and poorer survival in HNSCC remain the
mainstay of the TNM system: extent of the tumor and
the presence of neck metastases.17 Histologic ﬁndings,
such as extracapsular extension, perineural invasion,
and lymphovascular invasion are also correlated with
worse prognosis. Various immunohistochemical markers
have been studied as well.18
Recently it was shown19 that a gene signature in
breast cancer stem cells identiﬁed tumors with a worse
prognosis. The ability to differentiate a stem cell gene
signature in unfractionated tumor tissue from patients
with a poor prognosis suggests that these tumors con-
tain a higher frequency of cancer stem cells.
Applying methods successfully used to identify can-
cer stem cells in breast cancer and other solid tumors,
HNSCC tumors were previously shown to contain a
distinct population of cancer cells deﬁned by their lack
of expression of markers associated with non-tumor
cell lineages present within the tumors (hematopoietic
cells, endothelial cells, and ﬁbroblasts, referred to as
Linþ cells) and expression of CD44 (thus referred to
as ‘‘Lin-CD44þ cells’’). These cells had the ability to
produce tumors in immunocompromised mice, whereas
the Lin-CD44 population from the same patient sam-
ples did not have the ability to initiate tumors in mice.
Tumors initiated by the Lin-CD44þ population reca-
pitulated the original tumor heterogeneity, and serial
transplantation indicated self-renewal ability when
xenotransplanted into mice.20,21 Thus the Lin-CD44þ
cells in HNSCC possess properties classically attrib-
uted to stem cells. The importance of CD44 as a tu-
mor-initiating cell marker was also shown in studies
with cell lines rather than fresh human tissue.22,23
During the course of analyzing many HNSCCs, it
was observed that these tumors have a broad range of
Lin-CD44þ cell frequencies. Another observation was
that approximately 50% of tumors were successfully xen-
ografted into mice, even when implanting large numbers
of cells or tissue fragments. It was postulated that
HNSCC rich in Lin-CD44þ cells would correlate with a
worse prognosis because of a higher frequency of stem
cells, similar to the ﬁndings of the breast cancer study.19
It was also suggested that tumors that could be success-
fully xenografted in mice may represent a more aggres-
sive phenotype.
MATERIALS AND METHODS
Between February 2004, and November 2006, fresh
tumors were obtained from the resected tissue of
patients undergoing surgery for advanced head and
neck squamous cell carcinoma at Stanford University
Medical Center. The use of human tissues and animal
experiments were performed in accordance with proce-
dures and guidelines established by the Stanford Uni-
versity Institutional Review Board and Administrative
Panels for Laboratory Animal Care.
As reported earlier,20 a mouse xenograft model of
HNSCC was developed in which primary specimens
obtained from patients undergoing surgical resection
were collected fresh either from the primary tumor or
from metastatic lymph nodes. The specimen was
immersed in saline solution and kept refrigerated. It
was implanted within 24 hours under the skin of
Rag2/cytokine receptor common c-chain double knock-
out (Rag2 c DKO) mice, either as small (<2 mm) frag-
ments of tumor or as cell suspensions in 50%
matrigel (Becton Dickinson; Franklin Lakes, NJ),
ranging from 1 to 5 million total cells per injection.
There was no difference in success rate when
implanting as single cell digests or small, nondigested
tumor pieces. When the surgical specimen was sufﬁ-
ciently large and there was enough tissue for analy-
sis, ﬂow cytometry was performed from the human
tumor after dissociation into single cells. The single-
cell suspensions were washed in Hank’s balanced salt
solution (HBSS)/2% heat inactivated calf serum
(HICS) and counted and then resuspended in 100 lL
per 106 cells of HBSS and incubated with 1 mg/mL
mouse IgG (Sigma, St. Louis, MO) for 10 minutes.
The suspensions were then washed with HBSS/2%
HICS, resuspended in 100 lL per 106 cells of HBSS,
and stained with antibodies. Anti-CD44 (Pharred,
phycoerythrin-, or allophycocyanin-conjugated, clone
G44–26; BD Pharmingen) was used at a 1:50 dilution;
lineage markers anti-CD2, CD3, CD10, CD16, CD18,
CD31, CD64, and CD140b (all diluted 1:50; BD Phar-
mingen, Franklin Lakes, NJ) were used to allow iden-
tiﬁcation of contaminating nontumor cells from
patient samples. In each tumor analyzed by ﬂow
cytometry, a distinct population of Lin-CD44þ and
Lin-CD44– cancer cells was identiﬁable, and the per-
centage of Lin-CD44þ cells was recorded (Figure 1).
Clinical and pathologic data were collected,
including age, sex, alcohol and tobacco consumption,
site of tumor, TNM stage, prior treatment, and cur-
rent planned treatment (surgery/radiotherapy/chemo).
Histologic criteria were reviewed by 1 pathologist
(R.P.) and included grade, extracapsular spread, peri-
neural invasion, angiolymphatic invasion, and margins
of resection. Human papillomavirus status was not
recorded because only 4 tumors were from the oro-
pharynx. Patients were followed up every 4 to 6 weeks
for the ﬁrst year after diagnosis and every 8 to 12
weeks thereafter. If the patient did not appear for fol-
low-up, his primary care physician or referring
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otolaryngologist–head and neck surgeon was con-
tacted. Outcome was evaluated for site of failure (local,
regional or distant) and overall and disease-speciﬁc
survival.
Statistical Analysis. Results were evaluated for
normality. Correlations between continuous variables
were done with the Pearson or the Spearman coefﬁ-
cients of correlation, for parametric or nonparametric
groups, respectively. The best cut-off points for dis-
criminating between good and bad prognostic groups
were determined after applying receiver operating
characteristic analysis. The best cut-off point was
determined by (sensitivity  [1-speciﬁcity]), and sen-
sitivity was favored. Univariate analysis of survival
for the measured variables was performed by con-
structing Kaplan Meier curves, and statistical signiﬁ-
cance was tested by use of the log-rank test. Cox
proportional hazard model to evaluate parameters
that inﬂuence the survival of the patients was applied
to test which of the parameters found on a univariate
analysis was independent.
RESULTS
The following are examples of 4 patients, including a
brief history, treatment follow-up, and percentage of
Lin-CD44þ cells from the tumor specimen. In these
selected cases it can be appreciated that the patients
who did poorly also had a higher Lin-CD44þ fre-
quency in their tumors.
Patient A, a 52-year-old man, was initially seen
with a T2N2b (T/N/M classiﬁcation) squamous cell
carcinoma (SCC) of the left lateral tongue. He was
treated in July 2004 by partial glossectomy and modi-
ﬁed radical neck dissection. Pathologic study showed
moderately differentiated SCC, margins clear of tu-
mor, and 2/62 positive lymph nodes, with no perineu-
ral invasion or extracapsular invasion. The patient
underwent postoperative radiation. He was last seen
on July 2009 without evidence of disease. The Lin-
FIGURE 1. Flow cytometric analysis of a typical HNSCC sample. Cells are sequentially gated on (A) viable cells with either DAPI or
propidium iodide as a dead cell marker, then (B) doublets are excluded in a forward scatter area versus width proﬁle. The lineage neg-
ative cells are then excluded (C), and ﬁnally, the gate for CD44þ cells is drawn by use of a ‘‘ﬂuorescence-minus-one’’ control, in which
the CD44 antibody is excluded from the staining mixture (D). When this gate is applied to the CD44 stained sample, the frequency of
Lin-CD44þ cells is determined (E). In this case the frequency of Lin-CD44þ cells is 12.1%.
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CD44þ was 1.8%, and the tumor did not xenotrans-
plant into mice.
Patient B, a 54-year-old man, presented with a
T2N0M0 (T/N/M classiﬁcation) SCC of the right mobile
tongue. He was treated in October 2006 by partial glos-
sectomy. The pathologic study showed moderately dif-
ferentiated SCC with perineural invasion. After
surgery the patient underwent radiation to the tongue
and neck. On March 2007 a short interval recurrence
in the right neck was noted for which a modiﬁed radi-
cal neck dissection was performed. Pathologic examina-
tion revealed 1 positive node 2.5 cm with extracapsular
extension. As of January 2010 the patient is free of dis-
ease. The Lin-CD44þ from the ﬁrst surgery was 23%,
and the tumor was xenografted successfully.
Patient C, a 56-year-old woman, was previously
treated by chemotherapy and radiation for ﬂoor of
mouth SCC. There was recurrence in the ﬂoor of
mouth, T/N/M classiﬁcation T4aN2bM0. The patient
was treated by a composite resection and a modiﬁed
radical neck dissection and reconstruction with a ﬁb-
ula free ﬂap. Pathologic examination showed complete
resection with clear margins and no perineural inva-
sion or angiolymphatic invasion. In July 2007 local
recurrence was noted, and the patient underwent pal-
liative chemotherapy. She died in January 2008. The
Lin-CD44þ from the surgery (2007) was 78%, and the
tumor was xenografted successfully.
Patient D, a 35-year-old man, was diagnosed with
a T1N0M0 (T/N/M classiﬁcation) left lateral tongue
SCC that was treated in June 2005 by partial glossec-
tomy and left supraomohyoid neck dissection. Mar-
gins were not involved, and there were no positive
lymph nodes. In January 2006 a recurrence was
noted in the neck and tongue (rT2N3M0). The patient
was treated surgically with a partial glossectomy, par-
tial pharyngotomy, and left radical neck dissection.
The postoperative course was uneventful. During
urgent radiation planning, a neck recurrence was
noted. The patient died in May 2006. The Lin-CD44þ
frequency from the second surgery was 72.8%, and
the tumor was xenotransplanted successfully.
The study included 31 patients with HNSCC, with
a mean age of 61.5  2.8 years (mean  SEM) and a
mean follow-up of 12.9  1.14 months (mean  SEM),
range, 4.9–27 months. Twenty-four patients were
male, and seven patients were female. Out of this
group, 21 patients (68%) were newly diagnosed,
whereas 10 patients were treated because of recur-
rent disease. The primary sites and TNM stages are
shown in Table 1.
All patients had SCC: 4 were well differentiated
(13%), 19 were moderately differentiated (61%), and 8
were poorly differentiated (26%). Other pathologic pa-
rameters, such as perineural invasion, extracapsular
spread, and angiolymphatic invasion, are shown in
Table 2.
Subsequent failure occurred in 15 patients (48%):
local failure in 6 (19%), regional failure in 8 (26%),
and distant failure in 4 (13%). At the end of the
study, 22/31 patients (71%) were alive.
CD44 was examined in 22 patients, with a mean
Lin-CD44þ cell frequency of 25.4%5.4% (SEM), me-
dian 17%, (range 0.4-80.6%). Successful xenograft im-
plantation in RagcDKO mice was obtained for 16
tumors of 30 (53%).
Correlation of Frequency of Lin-CD441 Cells to
Pathologic Parameters. There was a trend toward
an inverse correlation between tumor grade and
mean Lin-CD44þ cell frequency: poorly differentiated
carcinoma 45.8%, moderately differentiated carci-
noma 21%, and well-differentiated carcinoma 11.8% (p
¼ .09; Table 2). A higher frequency of Lin-CD44þ cells
was found in patients with perineural invasion, as
well as angiolymphatic invasion, but these were not
found to be statistically signiﬁcant. There was no cor-
relation of extracapsular spread to Lin-CD44þ cell
frequency.
Correlation of Frequency of Lin-CD441 Cells to
Clinical Parameters. A signiﬁcant correlation was
found between T classiﬁcation and Lin-CD44þ cell fre-
quency, p ¼ .05: patients with T0-2 disease (7 patients)
had a mean frequency of 10.3% compared with T3-4
(15 patients) with a mean frequency of 32.4%. There
Table 1. Summary of parameters analyzed.
Parameter No. of patients (%)
Site
Oral cavity 13 (42%)
Skin or lip 8 (26%)
Oropharynx 4 (13%)
Larynx and hypopharynx 4 (13%)
Nose and sinuses 2 (6%)
T classiﬁcation
T0 3 (10%)
T1 1 (3%)
T2 6 (19%)
T3 7 (22%)
T4 14 (45%)
N classiﬁcation
N0 13 (42%)
N1 0 (0%)
N2 11 (35%)
N3 7 (23%)
Alcohol
>3 drinks/day 8 (26%)
1-3 drinks/day 10 (32%)
<1 drink/day 13 (42%)
Tobacco
>25 pack year 13 (42%)
1-25 pack year 6 (19%)
<1 pack year 12 (39%)
Lin-CD44þ cell frequency (n ¼ 22)
Mean  SD 25%  25% (0.4%-80.6%)
Median 17%
Successful xenograft (n ¼ 30)
Yes 16 (53%)
No 14 (47%)
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was no correlation of Lin-CD44þ cell frequency to N
classiﬁcation, nor to overall stage. No difference was
found in Lin-CD44þ cell frequency among the differ-
ent sites of head and neck carcinomas. There was a
trend toward increased frequency in patients who
were treated because of recurrent disease compared
with patients who had primary diagnosed tumors
(35.7% vs 18.3%, respectively), but it was not signiﬁ-
cant (p ¼ .1119).
The Lin-CD44þ cell frequency was signiﬁcantly
higher in patients with subsequent failure, compared
with patients without failure: 35.7% vs 15% (p ¼ .05).
Signiﬁcantly higher frequencies of Lin-CD44þ cells
were found in patients with local failure (43.2%) com-
pared with patients without local failure (18.7%; p ¼
.038, Table 2). Multivariate analysis showed that the
fraction of Lin-CD44þ was signiﬁcantly correlated to
failure (p ¼ .02).
An elevated frequency of Lin-CD44þ cells was also
found in patients with regional failure and distant fail-
ure; however, it was not signiﬁcant. The best cut-off
point for predicting overall failure was detected after
applying receiver operating characteristic analysis. The
best cut-off point of Lin-CD44þ cell frequency for dis-
criminating between good and bad prognostic groups
was 15.2%. Sensitivity: 0.91, speciﬁcity: 0.73, [sensitiv-
ity  (1-speciﬁcity)] ¼ 0.64, area under curve ¼ 0.818).
A Kaplan Meier curve for overall failure demonstrates
a signiﬁcantly lower incidence of failure in patients
with a Lin-CD44þ cell frequency <15% compared with
patients with a Lin-CD44þ cell frequency >15% (p ¼
.005, log-rank test; Figure 2).
Table 2. Correlation of Lin-CD44þ cell frequency and successful xenograft implantation to clinical and pathological parameters.
Parameter No. of patients Lin-CD44þ % (Mean  SEM) No. of patients Successful implantation
T classiﬁcation p ¼ .05 NS
T 0-2 7 10.3  3.5 9 5 (56%)
T 3-4 15 32.4  7.1 21 11 (52%)
N classiﬁcation NS NS
N0 10 23.98  6.01 13 7 (54%)
N2 6 21.43  12.2 10 5 (50%)
N3 6 31.58  13.2 7 4 (57%)
Site NS NS
Skin and lip 8 26.77  8.4 8 4 (50%)
Oral cavity 13 26.8  .12.2 12 8 (67%)
Oropharynx and nasopharynx 4 11.07  3.7 4 1 (25%)
Larynx and hypopharynx 4 32.77  24.4 4 1 (25%)
Nose and paranasal sinuses 2 33.45  1.65 2 2 (100%)
Failure p ¼ .05 p ¼ .009
No failure 11 15.06  6.8 15 4 (27%)
With failure 11 35.65  7.3 15 12 (80%)
Local failure p ¼ .03 NS
No local failure 16 18.66  5.9 24 12 (50%)
With local failure 6 43.20  8.5 6 4 (67%)
Regional failure NS p ¼ .003
No regional failure 17 21.84  5.4 22 8 (36%)
With regional failure 5 37.32  14.9 8 8 (100%)
Status p ¼ .11 NS
Alive 14 18.95  5.8 21 11 (56%)
Dead 8 36.58  10 9 5 (52%)
Previous treatment p ¼ .11 NS
Previous treatment 9 35.6  10.2 10 5 (50%)
No previous treatment 13 18.2  5.22 20 9 (45%)
Grade p ¼ .09 p ¼ .015
Well differentiated 3 11.80  1.8 4 0 (0%)
Moderately differentiated 14 20.96  6.5 18 9 (50%)
Poorly differentiated 5 45.82  11.4 8 7 (88%)
Perineural invasion p ¼ .12 Fisher p ¼ .13
Yes 15 30.98  2.02 18 12(67%)
No 7 13.31  5.9 12 4 (33%)
Extracapsular extension NS NS
Yes 8 29.0  10.7 9 5 (56%)
No 4 23.25  16.9 7 4 (57%)
Angiolymphatic invasion p ¼ .23 NS
Yes 6 35.88  13.7 8 5 (63%)
No 16 21.41  5.3 22 11 (50%)
Successful implantation p ¼ .009
No 11 13.52  3.7
Yes 10 40.81  9
Abbreviation: NS, not signiﬁcant.
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A Kaplan Meier curve for overall survival showed
signiﬁcant differences as well. Patients with a Lin-
CD44þ cell frequency <15% had an 88% overall sur-
vival rate at 27 months, compared with 30% at 18
months for patients with a Lin-CD44þ cell frequency
>15% (p ¼ .01, log rank test; Figure 3).
CD44 and Xenograft Implantation. A signiﬁcant
correlation was found between the frequency of Lin-
CD44þ cells and successful xenograft tumor implan-
tation into RagcDKO mice: the mean frequency of
Lin-CD44þ cells was 40.8% for successful xenograft
implantation, compared with 13.5% for those with
failed xenograft implantation (p ¼ .009).
Correlation of Xenograft Implantation to Pathologic
Parameters. Successful xenograft implantation was
signiﬁcantly correlated to tumor grade (p ¼ 0.015): none
of the 4 well-differentiated tumors were successfully xen-
ografted, compared with 50% (9 of 18) of the moderately
differentiated tumors and 88% (7 of 8) of the poorly differ-
entiated tumors. Higher xenograft rates were found for
tumors with perineural invasion (67%) compared with
those without perineural invasion (33%); however, it was
not signiﬁcant (Fisher exact test p ¼ .13).
Xenograft Implantation: Correlation to Clinical
Parameters. There was no correlation between suc-
cessful xenograft implantation and T classiﬁcation, N
classiﬁcation, overall stage, or site of tumor. There
was no difference in the percent of successful implan-
tation between patients who were newly diagnosed (9
successful implantations of 20 [45%]) compared with
patients who had previous treatment (5 successful
implantations of 10 [50%]).
There was a trend toward increased successful im-
plantation in patients who do not smoke, compared
with smokers: 9 of 12 (75%) non-smokers had success-
ful implantation, compared with 7 of 18 (39%) of
smokers (v2, p ¼ .05, Fisher exact test p ¼ .07). Suc-
cessful implantation was most signiﬁcantly correlated
to subsequent failure: 12 of 15 patients (80%) who
failed had successful implantation, compared with 4
of 11 (27%) of the patients who did not fail (Fisher
exact test p ¼ .009).
No signiﬁcant correlation was found between suc-
cessful implantation and local failure, but there was a
signiﬁcant correlation to regional failure (Fisher exact
test p ¼ .003): all patients with regional failure (8
patients, 100%) had successful implantation, compared
to 36% (8 of 22) of the patients without regional failure.
A Kaplan Meier curve was generated for overall failure,
stratiﬁed by successful implantation. A signiﬁcant dif-
ference was found in failure rate between patients with
successful implantation compared to those without im-
plantation (p ¼ .009, log-rank test; Figure 4). There
was no signiﬁcant difference in the survival rate of
patients whose tumor had successful implantation com-
pared with those whose tumor had not.
In Cox proportional hazard model to evaluate pa-
rameters that inﬂuence the survival of the patients,
including Lin-CD44þ and successful tumor implanta-
tion, Lin-CD44þ was a signiﬁcant and independent
FIGURE 2. Kaplan Maier analysis of disease control stratiﬁed by
Lin-CD44þ cell frequency<15% (n¼ 10) versus>15% (n¼ 12).
FIGURE 3. Kaplan Meier survival analysis stratiﬁed by Lin-
CD44þ cell frequency <15% (n ¼ 10) versus >15% (n ¼ 12).
FIGURE 4. Kaplan Maier Analysis of disease control stratiﬁed
by successful tumor implantation (n ¼ 16) versus unsuccessful
xenograft implantation (n ¼ 14) in RaggDKO mice.
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parameter that inﬂuenced survival, whereas success-
ful implantation was not signiﬁcant (p ¼ .049).
DISCUSSION
CD44 proteins are a widely expressed family of adhe-
sion molecules encoded by a single highly conserved
gene. The different family members are generated by
posttranslational modiﬁcations and extensive alterna-
tive splicing.24 The standard CD44 isoform (CD44s)
contains 10 of the 19 exons and is widely expressed.
The remaining exons are alternatively spliced and
incorporated into the standard backbone to create
several variant isoforms, which are expressed in a
variety of tissues at particular periods in develop-
ment, or in cancer cells. Previous studies have shown
conﬂicting results regarding the signiﬁcance of CD44
expression in head and neck tumors.25–35 Most stud-
ies found that using immunohistochemistry, underex-
pression of CD44, or one of the variants is a predictor
of reduced survival. In contrast, others have found
that CD44 is consistently highly expressed on all
head and neck tissues, from normal to HNSCC.36
These varying results are likely due to the use of dif-
ferent antibodies by different investigators, as well as
different methods of tissue processing, staining, and
enumeration of results. Given the complexity of the
molecule, the variation in results already present in
the literature, and the fact that our analysis was
done by an entirely different method (ie, ﬂow cytome-
try), it is not surprising that there are conﬂicts with
the published data. Some possible explanations for
these conﬂicts are likely due to two major differences
between our study and those previously described:
the use of a pan-CD44 antibody, and the use of ﬂow
cytometry. Many previous studies used antibodies for
speciﬁc variants of CD44. Although the expression of
speciﬁc variants may be reduced in tumors with a
worse prognosis, the overall CD44 expression may
not. It is of interest for future studies to determine
which variants of CD44 are expressed in the tumor-
initiating subset of head and neck cancer cells versus
normal oral squamous epithelial stem cells and how
differences in their expression patterns affect the
behavior of these cells. The use of ﬂow cytometry is a
highly quantitative method, compared with previous
studies that analyzed CD44 with immunohistochemis-
try and a subjective examiner-based analysis report-
ing positive or negative results on a semiquantitative
scale (for example, by assigning scores of /þ/þþ/
þþþ). CD44 is also highly expressed on stromal and
inﬂammatory cells, which we exclude when we per-
form ﬂow cytometric analysis (that is the Lin- compo-
nent of the analysis). Although it is possible on
histologic study to differentiate between tumor and
nontumor cells, it may not be as accurate at excluding
these. Finally, immunohistochemistry analyzes a sig-
niﬁcantly smaller number of cells and looks at only
small regions of the tumor; on the other hand, a large
piece of tumor is dissociated for ﬂow cytometry and
hundreds of thousands to millions of cells are run
through the machine, allowing us to typically acquire
at least 100,000 viable cell events for analysis.
Because the tumor was dissociated, the value we get
is an average across the whole tissue sample rather
than one thin section.
On the basis of previous studies showing that the
Lin-CD44þ fraction of HNSCC cells contains a cancer
stem cell population, our study suggests that a higher
frequency of cancer stem cells is associated with a
worse prognosis. This would support the theory that
stem cell burden and not overall tumor burden is the
important prognostic ﬁnding. This hypothesis is sup-
ported by a recent article demonstrating the impor-
tance of the stem cell signature in predicting
prognosis in breast cancer,19 where tumors with a
genetic signature similar to the breast cancer stem
cells had a worse prognosis. An alternative explana-
tion not relevant to a stem cell hypothesis is that the
CD44 protein is merely a marker for aggressiveness
of the tumor, and that CD44 plays a functional role in
tumor progression by mediating, for example, homing
or binding at sites of metastases. However, in support
of our hypothesis, it has also recently been shown
that aldehyde dehydrogenase (ALDH) activity can be
used as a HNSCC stem cell marker, with ALDHþ
cells representing 1% to 7.8% of tumor cells, and xen-
ografts initiated from as few as 500 cells.37,38 Chen
et al38 also showed that high ALDH1 protein levels
were positively associated with stage and grade of
HNSCC and with poor outcome. To determine
whether cancer stem cell frequency is truly a determi-
nant of patient outcome will require additional stud-
ies with limiting dilution assays to functionally
measure the cancer stem cell frequencies, as well as
the identiﬁcation of additional markers to identify
more precisely the cancer stem cell population, as has
been done in other cancers such as breast cancer and
leukemias.
This study suggests that successful tumor xeno-
graft in mice was also an important prognostic sign.
The frequency of Lin-CD44þ cells correlated with
successful implantation and therefore may explain
this ﬁnding. However, it seems there are other factors
as well, because the frequency of Lin-CD44þ cells cor-
related better with local recurrence whereas success
of implant correlated better with regional recurrence
(Table 2). In addition, tumor grade correlated better
with successful xenografting than with frequency of
Lin-CD44þ cells (Table 2). This implies that the suc-
cess of xenograft implants is related to other parame-
ters, such as ability to survive in a foreign
microenvironment, in addition to the frequency of
Lin-CD44þ cells in HNSCC.
Limitations and Future Directions. It should be
stressed that the ﬁndings in this study, although signif-
icant, are somewhat preliminary because only 31
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patients were recruited and the tumors were very
diverse, including nasal, skin, oral cavity, oropharynx,
and laryngohypopharynx. In addition we combined new
cases with recurrences. Because of the limited number
of patients, a meaningful multivariate analysis could
not be done. As we and others gather more patients to
the database, these ﬁndings can be further tested.
Sorting for Lin-CD44þ cells enriches the stem cell
population; however, to test the theory further the
population must be more reﬁned. The percentage of
actual stem cells is likely much lower than the fre-
quency of Lin-CD44þ cells reported in this study.
CONCLUSIONS
This study suggests that a ﬂow cytometric measure-
ment of the frequency of Lin-CD44þ cells may pro-
vide a prognostic test for patients with HNSCC. In
addition and arguably more importantly, it lends pre-
liminary support to the notion that to better under-
stand HNSCC tumor behavior, research should be
focused on the understanding of cancer stem cells,
the earliest steps of their dysregulation, and the de-
velopment of methods for their eradication.
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